OCA
ANAB icon

Octagon Capital Advisors’s AnaptysBio ANAB Stock Holding History

Octagon Capital Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-165,000
Closed -$3.72M – 48
2024
Q1 		$3.72M Buy
165,000
+45,000
+38% +$1.07M 0.45% 43
2023
Q4 		$2.57M Buy
+120,000
New +$2.07M 0.41% 27

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Octagon Capital Advisors's ANAB Position: Q2 2024 in Review

Octagon Capital Advisors sold out of AnaptysBio (ANAB) in Q2 2024, closing a stake of 165,000 shares — an estimated $3.72M sold.

Octagon Capital Advisors first reported a position in ANAB in Q4 2023 and held it in 2 quarters. The position peaked at $3.72M in Q1 2024. 135 funds tracked by Wall St. Rank hold ANAB as of Q2 2024.

  • Octagon Capital Advisors reported no remaining AnaptysBio position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 165,000 AnaptysBio shares in Q2 2024, an estimated $3.72M.
  • Octagon Capital Advisors first reported a position in AnaptysBio in Q4 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's AnaptysBio position peaked at $3.72M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.